How to achieve greener, faster and more cost-effective bioprocessing workflows 

Astrea Bioseparations has launched its Nereus LentiHERO lentiviral vector (LVV) purification technology commercially. Incorporating AstreAdept, the company’s proprietary nanofiber material, this solution has been created to address the challenges associated with purifying the large and fragile products used in cell and gene therapy.

AstreAdept is a proprietary bioseparations material that utilises nanofiber technology which enables biologics manufacturers to reduce process times, increase process efficiency, reduce buffer consumption, and consequently improve waste treatment costs. As a result, Astrea Bioseparations says greener, faster, and more cost-effective bioprocessing workflows are possible.

Official comments

“We believe that AstreAdept will be a game-changer,” explained Astrea Bioseparations’ CEO Terry Pizzie. “Our approach was to rapidly develop and incorporate this material into the Nereus LentiHERO, a simple, fit-for-purpose device that radically transforms how lentivirus can be purified [in terms of speed, recovery, and efficiency].”

He added, “This launch also sets the stage for a future where cutting-edge therapies can make it into the hands of patients faster and more affordably than ever.”

Related Articles

Join FREE today and become a member
of Drug Discovery World

Membership includes:

  • Full access to the website including free and gated premium content in news, articles, business, regulatory, cancer research, intelligence and more.
  • Unlimited App access: current and archived digital issues of DDW magazine with search functionality, special in App only content and links to the latest industry news and information.
  • Weekly e-newsletter, a round-up of the most interesting and pertinent industry news and developments.
  • Whitepapers, eBooks and information from trusted third parties.
Join For Free